uniQure (NASDAQ:QURE) Shares Down 4.9% After Analyst Downgrade

uniQure N.V. (NASDAQ:QURE) traded down 4.9% on Monday after Barclays lowered their price target on the stock from $31.00 to $25.00. Barclays currently has an equal weight rating on the stock. uniQure traded as low as $15.56 and last traded at $15.3020. 728,277 shares were traded during mid-day trading, a decline of 79% from the average session volume of 3,510,736 shares. The stock had previously closed at $16.09.

Other research analysts have also recently issued research reports about the company. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Stifel Nicolaus set a $14.00 target price on shares of uniQure in a research report on Monday, March 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Tuesday, March 10th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $42.75.

Insider Transactions at uniQure

In other uniQure news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 81,399 shares of company stock valued at $1,527,645. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Swiss National Bank bought a new stake in uniQure during the 2nd quarter worth $1,080,000. Sanders Morris Harris LLC bought a new position in uniQure in the third quarter valued at about $5,081,000. Vanguard Group Inc. raised its position in uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after purchasing an additional 152,417 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after purchasing an additional 189,029 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

The company has a fifty day moving average price of $20.45 and a two-hundred day moving average price of $29.63. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The company has a market capitalization of $995.48 million, a P/E ratio of -4.61 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. Equities analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.